Skip to content
Screener
ODT

Odyssey Therapeutics

ODTX

Odyssey Therapeutics is a biotechnology company in the healthcare sector trading on XNAS, led by CEO Gary D. Glick, with a market cap of $1.0B.

Market cap
$1B+29.5%
Revenue$2.9M—
Net income-$170.7M—
Free cash flow-$149.7M—
EPS (diluted)-$77.42—
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 5, 2026
Revenue-EPS-$6.75Miss by $5.92

Next report

Sep 16, 2026 (in a month)
EPS estimate-$0.83

Financials

Q2 2026

Income statement

See full
Revenue--100%
Operating income-$55.5M-32.3%
Net income-$52.8M-28.0%
EPS (diluted)-$1.74+94.1%

Balance sheet

See full
Cash & equivalents$82.0M-49.7%
Total debt$24.8M+8,175%
Total equity$421.2M+197%
Total assets$483.9M—

Cash flow

See full
Operating cash flow-$34.5M-0.7%
CapEx$186.0K+541%
Free cash flow-$34.7M-1.2%

Valuation & ratios

Valuation

See full
Market cap$1B+29.5%
Enterprise value$946.17M—
P/S348.8×—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio11.4×—

Profile

CountryUnited States of America
Listed2026
CEOGary D. Glick
SectorHealthcare
IndustryBiotechnology
Websiteodysseytx.com
FilingsSEC EDGAR

FAQ

What is Odyssey Therapeutics's market cap?
Odyssey Therapeutics (ODTX) has a market capitalization of $1.0B and trades on XNAS.
What is Odyssey Therapeutics's revenue and profitability?
Odyssey Therapeutics generated $2.9M in trailing twelve-month revenue with a net loss of $170.7M, representing a net margin of -5934.0%, with free cash flow of -$149.7M. These figures are based on the Q2 2026 filing.
Where is Odyssey Therapeutics headquartered?
Odyssey Therapeutics is headquartered in United States of America. It has been publicly traded since 2026.